← Leaderboards
Chiara Giannarelli
Icahn School Of Medicine At Mount Sinai
$8,992,836
Attributed
$9,331,836
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,331,836 · 8
By mechanism
R01$6,456,521 · 2
K23$781,630 · 1
R21$678,000 · 1
UH2$677,996 · 1
U34$398,689 · 1
R03$169,500 · 1
Top collaborators
- Johan M Bjorkegren2 shared
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Jean Kyou Lim$13,225,849
- Johan M Bjorkegren$3,577,334
- Bishuang Cai$6,575,722
- Stephen R Salton$16,387,402
- Minghui Wang$1,519,632
Others in their field
Top investigators on “Arterial Fatty Streak”
- Gary K Owens · University Of Virginia$30,274,380
- Steven Kyle Grinspoon · Massachusetts General Hospital$26,498,890
- Pamela Susan Douglas · Duke University$25,743,317
- Ira A Tabas · Columbia University Health Sciences$24,470,195
- Zahi A. Fayad · Mount Sinai School Of Medicine Of Nyu$23,649,165
- Alan Richard Tall · Columbia University Health Sciences$22,240,124
Research focus
Arterial Fatty StreakAtherosclerosisCellsCardiovascular SystemPhenotypeMolecularEventPublic HealthCoronary ArteriosclerosisFutureMediatingImmuneTissuesMortalityStrokeAffectGenesDisabilityMolecular TargetMacrophagePreventLipidsInflammationDesign
Grant awards (22)
Mechanisms of atherosclerotic cardiovascular complications$783,846
R01 · FY2025 · HL · contact PI
Mechanisms of atherosclerotic cardiovascular complications in COVID19$768,169
R01 · FY2024 · HL · contact PI
Dissecting the role of CD8+ T cells in atherosclerosis$652,158
R01 · FY2024 · HL · contact PI
Mechanisms of atherosclerotic cardiovascular complications in COVID19$783,846
R01 · FY2023 · HL · contact PI
Dissecting the role of CD8+ T cells in atherosclerosis$665,467
R01 · FY2023 · HL · contact PI
Mechanisms of atherosclerotic cardiovascular complications in COVID19$803,677
R01 · FY2022 · HL · contact PI
Dissecting the role of CD8+ T cells in atherosclerosis$667,760
R01 · FY2022 · HL · contact PI
Dissecting the role of CD8+ T cells in atherosclerosis$677,514
R01 · FY2021 · HL · contact PI
Network-driven drug repurposing in cardiovascular disease: NDRA clinical trial planning$398,689
U34 · FY2021 · TR · contact PI
Dissecting the role of CD8+ T cells in atherosclerosis$654,084
R01 · FY2020 · HL · contact PI
Single-cell-driven drug repositioning approaches to target inflammation in atherosclerosis$169,500
UH3 · FY2019 · TR · contact PI
Single-cell-driven drug repositioning approaches to target inflammation in atherosclerosis$338,998
UH2 · FY2018 · TR · contact PI
Network-driven drug repurposing approaches to treat coronary artery disease$339,000
R21 · FY2017 · TR · contact PI
Single-cell-driven drug repositioning approaches to target inflammation in atherosclerosis$338,998
UH2 · FY2017 · TR · contact PI
Role of alternatively spliced Tissue Factor in atherosclerosis$177,305
K23 · FY2017 · HL · contact PI
Dissecting the cellular and molecular immune interactions in human atherosclerosis$84,750
R03 · FY2017 · HL · contact PI
Network-driven drug repurposing approaches to treat coronary artery disease$339,000
R21 · FY2016 · TR · contact PI
Role of alternatively spliced Tissue Factor in atherosclerosis$177,305
K23 · FY2016 · HL · contact PI
Dissecting the cellular and molecular immune interactions in human atherosclerosis$84,750
R03 · FY2016 · HL · contact PI
Role of alternatively spliced Tissue Factor in atherosclerosis$142,340
K23 · FY2015 · HL · contact PI
Role of alternatively spliced Tissue Factor in atherosclerosis$142,340
K23 · FY2014 · HL · contact PI
Role of alternatively spliced Tissue Factor in atherosclerosis$142,340
K23 · FY2013 · HL · contact PI